Matthew Roden

UBS Investment Bank

Matthew Roden is an Executive Director and Senior Analyst at UBS, leading coverage of large- and smid-cap biotechnology stocks. He joined UBS in 2010 and was named as a 2011 Institutional Investor All-America Research Team Rising Star in biotechnology. Previously, Dr. Roden was a lead small- to mid-cap biotech Analyst at Bank of America Merrill Lynch as well as J.P. Morgan, where he also served as the Vice President on the Institutional Investor, number-two-ranked biotech franchise. He holds a Ph.D. in microbiology and immunology from the Albert Einstein College of Medicine and was awarded a fellowship at the National Cancer Institute, where he studied cancer vaccines. Dr. Roden also holds an M.S. from Georgetown University and a B.S. from George Mason University.

Hepatitis C Therapies Propel Growth in Biotech
September 17, 2012 - Pharmaceuticals

Latest News

Sarepta Therapeutics Inc’s (SRPT) Technology Shows Dramatic Results as DMD Patients Regain Functions

FLIR Systems (FLIR) and Verint Systems (VRNT) May Hold Long-Term Value Despite Challenges in Defense Analytics

Sunoco Logistics Partners L.P.’s (SXL) Insider Buying and Value Investor Following: Is SXL Still a Special Situation?

C.R. Bard, Inc. (BCR) Generates ROE in the 20s; Trades at 7% Free Cash Flow Yield

Primary Energy Recycling Corporation (TSE:PRI) Generates Electricity from Waste Heat to Reduce Costs

Enercare (TSE:ECI) High-Growth Submetering Business Supports Dividend

Opportunities in Hepatitis C and Genomic Technologies

David Ferreiro

Published April 26, 2014 in Biotechnology and Pharmaceuticals

Companies covered:
GILD
ABBV
BIIB
CELG
AMGN
ILMN
LIFE
FLDM
RHO.DE
ARIA
BMY
ABT
ALXN
YMI
ACHN

Buy ($75)

Investing in Health Care Innovation

Finny Kuruvilla

"We’re a faith-based and socially responsible investing firm"

Published May 16, 2013 in Investing in Health Care

Companies covered:
DNDN
PCYC
SRPT
JNJ
CELG
BIIB
PFE
MRK

Buy ($75)

A Health Sciences Fund with a Long-Term Focus

Mark W. Oelschlager

"The fund is about $40 million in assets"

Published May 16, 2013 in Investing in Health Care

Companies covered:
BCR
BDX
BIIB

Buy ($75)

High-Yield Canadian Power Companies

John McIlveen

Published May 14, 2013 in High-Yield Equity Securities

Companies covered:
AT
NPI.TO
INE.TO
JE
ECI.TO
CPST
AQN.TO
BEP-UN.TO
PRI.TO

Buy ($75)

Investing in Health Care

Published May 16, 2013

Topics Covered: Health Care - Electronic Health Record Adoption - Biotechnology and Pharmaceutical Investing - Biotechnology and Pharmaceuticals - Biotechnology and Pharmaceutical Companies Valuation - Platform Interoperability and Data Analytics - HITECH Act Incentives - Affordable Care Act

Buy ($175)

Internet Services

Published May 10, 2013

Topics Covered: Increased Mobile Content Traffic - Chinese Online Monetization Trends - Internet Infrastructure and Services Consolidation - Social Networking Economics -

Buy ($175)

Investing Strategies

Published May 10, 2013

Topics Covered: Investing in Financial Services - Long-Term Investing - Large Cap Investing - Value Investing - High Quality Companies - Bottom-up Investing - All-Cap Growth Investing - Investing in Emerging Markets

Buy ($175)